Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2018 pubmed 16 citations

Ceragenin CSA-13 as free molecules and attached to magnetic nanoparticle surfaces induce caspase-dependent apoptosis in human breast cancer cells via disruption of cell oxidative balance.

Piktel. Ewelina E; Prokop. Izabela I; Wnorowska. Urszula U; Król. Grzegorz G; Cieśluk. Mateusz M; Niemirowicz. Katarzyna K; Savage. Paul B PB; Bucki. Robert R

Key Findings

  • CSA-13 and MNP@CSA-13 lowered survival of MCF-7 and MDA-MB-231 breast cancer cells
  • Treatment caused glutathione loss, increased reactive oxygen species, and mitochondrial damage
  • These changes led to caspase activation and DNA fragmentation, resulting in apoptosis

Practical Outcomes

  • The results are interesting for cancer research but not directly usable for personal health or longevity protocols. CSA-13 is not an approved supplement, and the study was done in cell cultures, so no dosage or safety guidance for humans can be drawn. Biohackers should view this as early‑stage science rather than a ready‑to‑try intervention.

Summary

A lab study found that a synthetic molecule called ceragenin CSA-13, and the same molecule stuck onto tiny magnetic particles, can kill two types of breast cancer cells in a dish by messing up the cells' antioxidant balance and triggering cell death pathways.

Abstract

Natural antimicrobial peptides and ceragenins, as non-peptide amphipathic mimics, have been proposed as anti-cancer agents. To date, it has been confirmed that cathelicidin LL-37 and ceragenin CSA-13, both in free form and immobilized on the surface of magnetic nanoparticles (MNP@LL-37, MNP@CSA-13) induce apoptosis in colon cancer cells. Nevertheless, the question remains whether ceragenins, as synthetic analogs of LL-37 peptide and mimicking a number of its properties, act as antineoplastic agents in breast cancer cells, where LL-37 peptide stimulates oncogenesis. Considering potential anticancer activity, we determined whether CSA-13 and MNP@CSA-13 might be effective against breast cancer cells. Our study provides evidence that both CSA-13 and MNP@CSA-13 decreased viability and inhibit proliferation of MCF-7 and MDA-MB-231 cells despite the protumorigenic properties of LL-37 peptide. Flow cytometry-based analyses revealed that ceragenin treatment results in increases in dead and PI-negative/low-viability cells, which was associated with glutathione (GSH) depletion and increased reactive oxygen species (ROS) generation followed by mitochondrial membrane depolarization, caspase activation, and DNA fragmentation. These findings demonstrate that both CSA-13 and MNP@CSA-13 cause disruption of the oxidative balance of cancer cells. This novel mechanism of ceragenin-mediated eradication of cancer cells suggest that these agents may be developed as a possible treatment of breast cancer.

Study Information

Provider

pubmed

Year

2018

Date

2018-04-24T00:00:00.000Z

DOI

10.18632/oncotarget.25105

Citations

16

References

54